Screener
Kura Oncology KURA Product — Cost Of Product Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept kura:CostOfProductSales.
The source filing: Kura Oncology’s 10-K, filed March 5, 2026.
- Filed
- Mar 5, 2026, 7:31 AM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-092567
| Line item | Years Ended December 31, 2025 | Years Ended December 31, 2024 | Years Ended December 31, 2023 |
|---|---|---|---|
| Collaboration revenue | 65,350 | 53,883 | — |
| Total revenue | 67,482 | 53,883 | — |
| Operating Expenses | |||
| Cost of product sales | 57 | — | — |
| Research and development | 251,074 | 169,967 | 115,235 |
| Selling, general and administrative | 119,982 | 77,111 | 50,569 |
| Total operating expenses | 371,113 | 247,078 | 165,804 |
| Loss from operations | (303,631) | (193,195) | (165,804) |
Item 16. Form 10-K Summary.
FAQ
- What is Kura Oncology's product — cost of product sales?
- Kura Oncology (KURA) reported product — cost of product sales of $14.25K in Q4 2025.
- What does product — cost of product sales mean?
- This metric captures the direct costs incurred to manufacture, package, and distribute the pharmaceutical products sold within a specific business segment. It includes expenses such as raw materials, direct labor, and manufacturing overhead directly attributable to the production of goods. Monitoring this figure is essential for evaluating the gross margin profile and the underlying cost efficiency of the company's commercial operations as it scales its product offerings.
Ask your AI about Kura Oncology's product — cost of product sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude